218 related articles for article (PubMed ID: 28911508)
1. Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation.
Pastori D; Nocella C; Farcomeni A; Bartimoccia S; Santulli M; Vasaturo F; Carnevale R; Menichelli D; Violi F; Pignatelli P;
J Am Coll Cardiol; 2017 Sep; 70(12):1455-1462. PubMed ID: 28911508
[TBL] [Abstract][Full Text] [Related]
2. Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation.
Pastori D; Pignatelli P; Farcomeni A; Cangemi R; Hiatt WR; Bartimoccia S; Nocella C; Vicario T; Bucci T; Carnevale R; Lip GY; Violi F
Am Heart J; 2015 Sep; 170(3):490-7.e1. PubMed ID: 26385032
[TBL] [Abstract][Full Text] [Related]
3. Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillation.
Pastori D; Pignatelli P; Farcomeni A; Nocella C; Bartimoccia S; Carnevale R; Violi F
Oncotarget; 2016 Jun; 7(26):39143-39147. PubMed ID: 27270651
[TBL] [Abstract][Full Text] [Related]
4. Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort.
Pastori D; Ettorre E; Carnevale R; Nocella C; Bartimoccia S; Del Sordo E; Cammisotto V; Violi F; Pignatelli P;
Atherosclerosis; 2019 Oct; 289():195-200. PubMed ID: 31303312
[TBL] [Abstract][Full Text] [Related]
5. Mediterranean diet reduces thromboxane A2 production in atrial fibrillation patients.
Pignatelli P; Pastori D; Farcomeni A; Nocella C; Bartimoccia S; Vicario T; Bucci T; Carnevale R; Violi F
Clin Nutr; 2015 Oct; 34(5):899-903. PubMed ID: 25288566
[TBL] [Abstract][Full Text] [Related]
6. Gut-Derived Serum Lipopolysaccharide is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet.
Pastori D; Carnevale R; Nocella C; Novo M; Santulli M; Cammisotto V; Menichelli D; Pignatelli P; Violi F
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28584074
[TBL] [Abstract][Full Text] [Related]
7. Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
El Khoury P; Roussel R; Fumeron F; Abou-Khalil Y; Velho G; Mohammedi K; Jacob MP; Steg PG; Potier L; Ghaleb Y; Elbitar S; Ragot S; Andreata F; Caligiuri G; Hadjadj S; Boileau C; Marre M; Abifadel M; Varret M; Hansel B
Diabetes Obes Metab; 2018 Apr; 20(4):943-953. PubMed ID: 29205760
[TBL] [Abstract][Full Text] [Related]
8. Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study.
Silbernagel G; Scharnagl H; Kleber ME; Stojakovic T; März W
Eur J Prev Cardiol; 2017 Jul; 24(10):1095-1101. PubMed ID: 28436724
[TBL] [Abstract][Full Text] [Related]
9. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors.
Pastori D; Pignatelli P; Angelico F; Farcomeni A; Del Ben M; Vicario T; Bucci T; Raparelli V; Cangemi R; Tanzilli G; Lip GYH; Violi F
Chest; 2015 Jun; 147(6):1644-1650. PubMed ID: 25429521
[TBL] [Abstract][Full Text] [Related]
10. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.
Leander K; Mälarstig A; Van't Hooft FM; Hyde C; Hellénius ML; Troutt JS; Konrad RJ; Öhrvik J; Hamsten A; de Faire U
Circulation; 2016 Mar; 133(13):1230-9. PubMed ID: 26896437
[TBL] [Abstract][Full Text] [Related]
11. Urinary 11-Dehydro-Thromboxane B2 as a Predictor of Acute Myocardial Infarction Outcomes: Results of Leukotrienes and Thromboxane In Myocardial Infarction (LTIMI) Study.
Szczeklik W; Stodółkiewicz E; Rzeszutko M; Tomala M; Chrustowicz A; Żmudka K; Sanak M
J Am Heart Assoc; 2016 Aug; 5(8):. PubMed ID: 27481134
[TBL] [Abstract][Full Text] [Related]
12. Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
Ridker PM; Rifai N; Bradwin G; Rose L
Eur Heart J; 2016 Feb; 37(6):554-60. PubMed ID: 26508163
[TBL] [Abstract][Full Text] [Related]
13. Association of proprotein convertase subtilisin/kexin type 9 (PCSK9) levels with abnormally high ankle-brachial index in atrial fibrillation.
Menichelli D; Galardo G; Cammisotto V; Bartimoccia S; Carnevale R; Pignatelli P; Pastori D
Kardiol Pol; 2023; 81(4):381-387. PubMed ID: 36929300
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients.
Nagatsuka K; Miyata S; Kada A; Kawamura A; Nakagawara J; Furui E; Takiuchi S; Taomoto K; Kario K; Uchiyama S; Saito K; Nagao T; Kitagawa K; Hosomi N; Tanaka K; Kaikita K; Katayama Y; Abumiya T; Nakane H; Wada H; Hattori A; Kimura K; Isshiki T; Nishikawa M; Yamawaki T; Yonemoto N; Okada H; Ogawa H; Minematsu K; Miyata T
Thromb Haemost; 2016 Aug; 116(2):356-68. PubMed ID: 27098431
[TBL] [Abstract][Full Text] [Related]
15. Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF Study Cohort.
Pastori D; Pignatelli P; Menichelli D; Violi F; Lip GYH
Mayo Clin Proc; 2019 Jul; 94(7):1261-1267. PubMed ID: 30551910
[TBL] [Abstract][Full Text] [Related]
16. PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention.
Paciullo F; Momi S; Gresele P
Thromb Haemost; 2019 Mar; 119(3):359-367. PubMed ID: 30605918
[TBL] [Abstract][Full Text] [Related]
17. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.
Pastori D; Pignatelli P; Saliola M; Carnevale R; Vicario T; Del Ben M; Cangemi R; Barillà F; Lip GY; Violi F
Int J Cardiol; 2015 Dec; 201():513-6. PubMed ID: 26318513
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation.
Cammisotto V; Pastori D; Nocella C; Bartimoccia S; Castellani V; Marchese C; Scavalli AS; Ettorre E; Viceconte N; Violi F; Pignatelli P; Carnevale R
Antioxidants (Basel); 2020 Apr; 9(4):. PubMed ID: 32252393
[TBL] [Abstract][Full Text] [Related]
19. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study.
Peng J; Liu MM; Jin JL; Cao YX; Guo YL; Wu NQ; Zhu CG; Dong Q; Sun J; Xu RX; Li JJ
Cardiovasc Diabetol; 2020 Oct; 19(1):167. PubMed ID: 33023603
[TBL] [Abstract][Full Text] [Related]
20. Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.
Ruscica M; Ferri N; Fogacci F; Rosticci M; Botta M; Marchiano S; Magni P; D'Addato S; Giovannini M; Borghi C; Cicero AFG;
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28468788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
